source
- FDA grants Capricor three-month extension to review DMD cell therapy dataThe U.S. Food and Drug Administration has given Capricor Therapeutics an additional three months to evaluate its Duchenne muscular dystrophy cell therapy after the agency asked for more information…
- FDA expands labels for J&J’s Imaavy and Jazz’s Ziihera; Teva under Turkish antitrust probeThe U.S. Food and Drug Administration has broadened the approved uses for Johnson & Johnson’s oncology drug Imaavy and Jazz Pharmaceuticals’ Ziihera, adding new indications to each label. These la…